X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
TNX-8011 (recombinant horsepox virus, live vaccine) is a potential vaccine to protect against mpox disease (formerly known as monkeypox) and smallpox.
Lead Product(s): Tnx-801
Therapeutic Area: Infections and Infectious Diseases Product Name: TNX-801
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 21, 2023
Details:
TNX-801 is a live virus vaccine based on horsepox. Tonix is developing TNX-801 for percutaneous administration as a vaccine to protect against monkeypox and smallpox
Lead Product(s): Tnx-801
Therapeutic Area: Infections and Infectious Diseases Product Name: TNX-801
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2023
Details:
TNX-801 is a live virus vaccine that is believed to be closer to the smallpox vaccines used in the U.S. and Europe before 1900 than the modern vaccinia smallpox vaccines.
Lead Product(s): Tnx-801
Therapeutic Area: Infections and Infectious Diseases Product Name: TNX-801
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Kenya Medical Research Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 28, 2022
Details:
TNX-801 is a live virus vaccine based on synthesized horsepox, was synthesized2 based on the sequence of the 1976 natural isolate Mongolian horsepox clone MNR-763.
Lead Product(s): Tnx-801
Therapeutic Area: Infections and Infectious Diseases Product Name: TNX-801
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: University of Alberta
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Details:
TNX-801 is a horsepox-based live virus vaccine currently in development to protect against monkeypox and smallpox, also has previously reported positive data from a monkeypox challenge study in non-human primates.
Lead Product(s): Tnx-801
Therapeutic Area: Infections and Infectious Diseases Product Name: TNX-801
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
The poster presentation reports that all animals (eight of eight) vaccinated with TNX-801 were fully protected with sterilizing immunity from a challenge with intra-tracheal monkeypox.
Lead Product(s): Tnx-801
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2020
Details:
Synthetic Chimeric Horsepox Virus (scHPXV) vaccination protects macaques from monkeypox.
Lead Product(s): Tnx-801
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
